Skip to main content

Anesthetic management of living-donor lung transplantation for end-stage COVID-19 lung failure

To the editor:

The coronavirus disease 2019 (COVID-19) pandemic remains ongoing [1]. Lung transplantation is a potentially life-saving treatment for end-stage post-COVID-19 lung failure [2,3,4]. Few brain-dead donor organs are available in Japan; therefore, living-donor lung transplantation (LDLT) plays a vital role in such cases. We report the first case of anesthetic management of LDLT for post-COVID-19 respiratory failure.

A 57-year-old woman was on veno-venous extracorporeal membrane oxygenation (VV-ECMO) due to severe post-COVID-19 lung injury, even after systemic inflammation subsided. Three months after disease onset, she was transferred to our institution for LDLT, as she recovered to the point where she could actively engage in rehabilitation. She had a Glasgow Coma Scale score of E4VTM6, blood pressure of 105/69 mmHg, and a sinus heart rate of 80/min. The patient breathed spontaneously through a tracheostomy. Gaseous exchange was completely dependent on VV-ECMO, and her oxygen saturation (SpO2) was 93% under room air. She had a short neck with limited mobility and her mouth opened to only about 1.5 horizontal fingers. Blood examination revealed anemia, thrombocytopenia, decreased fibrinogen levels, and increased D-dimer levels, presumably due to prolonged ECMO use. The activated partial thromboplastin time (APTT) was prolonged on 14,400–16,320 units/day of heparinization (Table 1). She had unimpaired biventricular function with no valvular disease.

Table 1 Blood examination on transfer to our institution

General anesthesia was induced with 5 mg of midazolam, 250 μg of fentanyl, and 100 mg of rocuronium and maintained with propofol and remifentanil. A 35Fr double-lumen tube was inserted orally using a McGRATHTM. An arterial line was placed in the right radial artery. Pulmonary and central venous catheters were inserted into the left internal jugular vein. Although most previous cases reporting dead-donor lung transplantation switched from VV-ECMO to VA-ECMO perioperatively, cardiopulmonary bypass (CPB) was established to avoid the lethal risk of circuit failure on switching due to insufficient evacuation or air suctioning upon venous cannulation into the right atrium. After the right lower lobe from her son and the left from her husband were transplanted, she was weaned from CPB under 4 mcg/kg/min of dobutamine and 0.05 mcg/kg/min of noradrenaline. She did not require ECMO support postoperatively. Anesthesia and operation times were 812 and 657 min, respectively. The estimated blood loss was 12,370 mL and urine output was 1410 mL. Crystalloid and colloid infusions were 1900 mL and 2000 mL, respectively. The patient was transfused with packed red cells (3360 mL), fresh frozen plasma (5040 mL), and platelet concentrates (800 mL). Cefozopran, levofloxacin, and micafungin were administered perioperatively for a week, referring to the serum creatinine level. The heparin was not administered due to concerns about postoperative hemorrhage. She was discharged from the intensive care unit on postoperative day (POD) 26. Although weaning from mechanical ventilation took approximately 2 months, she recovered well and was transferred to a rehabilitation hospital on POD 131. Our case indicates that anesthetic management for LDLT for end-stage COVID-19 lung failure is not essentially different from that indicated for other end-stage lung failures, except that the severe tissue adhesion and coagulopathy specific to COVID-19 would cause massive bleeding.

Availability of data and materials

Not applicable.

Abbreviations

COVID-19:

Coronavirus disease 2019

LDLT:

Living-donor lung transplantation

VV-ECMO:

Veno-venous extracorporeal membrane oxygenation

SpO2 :

Oxygen saturation

APTT:

Activated partial thromboplastin time

CPB:

Cardiopulmonary bypass

References

  1. Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, El-Ella MAD, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54:524–40. https://doi.org/10.1080/07853890.2022.2031274.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Hawkins RB, Mehaffey JH, Charles EJ, Mannem HC, Roeser M. Lung transplantation for severe post-coronavirus disease 2019 respiratory failure. Transplantation. 2021;105:1381–7. https://doi.org/10.1097/TP.0000000000003706.

    CAS  Article  PubMed  Google Scholar 

  3. Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon R, Kim S, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021;9:487–497. https://doi.org/https://doi.org/10.1016/S2213-2600(21)00077-1

  4. Roach A, Chikwe J, Catarino P, Rampolla R, Noble PW, Megna D, et al. Lung transplantation for Covid-19-related respiratory failure in the United States. N Engl J Med. 2022. https://doi.org/10.1056/NEJMc2117024.

Download references

Acknowledgements

Not applicable.

Funding

No funding.

Author information

Affiliations

Authors

Contributions

SS and KK were responsible for the anesthetic management of the patient. SS wrote the manuscript. KK helped in writing the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Satoshi Shimizu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written consent to report this case was obtained from both the donor and recipient.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shimizu, S., Kimura, K. Anesthetic management of living-donor lung transplantation for end-stage COVID-19 lung failure. JA Clin Rep 8, 21 (2022). https://doi.org/10.1186/s40981-022-00512-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40981-022-00512-9